RenovoRx, Inc. - Common Stock (RNXT)

Let's have a look at what is happening on the US markets before the opening bell on Friday. Below you can find the top gainers and losers in today's pre-market session.

RenovoRx (NASDAQ:RNXT) Q2 2025 revenue beats estimates at $422K, shares rise 4.8%. RenovoCath adoption grows, Phase III trial progresses. Strong cash position supports operations.

RNXT stock results show that RenovoRx met analyst estimates for earnings per share the second quarter of 2024.

RNXT stock results show that RenovoRx beat analyst estimates for earnings per share the first quarter of 2024.

The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.

Discover the top movers in Friday's pre-market session and stay informed about market dynamics.

RNXT stock results show that RenovoRx met analyst estimates for earnings per share the fourth quarter of 2023.

Let's have a look at what is happening on the US markets after the closing bell on Thursday. Below you can find the top gainers and losers in today's after hours session.

Pre-market stock movers are worth checking out as we get into all of the hottest news investors need to know about on Tuesday morning!

Shares of Longboard Pharmaceuticals, Inc.